Main Menu

Zynerba Pharmaceuticals, Inc.

(NASDAQ CM: ZYNE)

Rigrodsky Law, P.A. is investigating Zynerba Pharmaceuticals, Inc. (“Zynerba”) regarding possible breaches of fiduciary duties and other violations of law related to Zynerba’s agreement to be acquired by Harmony Biosciences Holdings, Inc. Under the terms of the agreement, Zynerba shareholders will receive $1.1059 per share in cash.  

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to info@rl-legal.com.

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 04/25/2024


* Indicates a required field.

Back to Page